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Nearly 36 million people live with the human immunodeficiency virus (HIV). Despite incredible
advances in combined antiretroviral therapy, the hopes for a definitive cure and an effective vaccine
have been frustrated by the seemingly endless capacity of the virus to subvert the host defenses, to
persist in a latent state, and to resist drug interventions. Recent work, however, sheds new light on
the pathogenesis of infection and unveils new tools to combat the ultimate enemy—the latent virus.HIV-1 particles assembling at the surface
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Paul Bieniasz.HIV Crosses the Monkey Barrier
Viral adaptation to a new host requires overcoming natural barriers to infection
presented by host restriction factors. The HIV exhibits very narrow tropism, which
reduces the risk of zoonoses but also limits the use of animal models to study
the dynamics of infection and the development of acquired immunodeficiency syn-
drome (AIDS). Paul Bieniasz and colleagues now show that it is possible to adapt
HIV-1 to productively infect and cause AIDS in monkeys. The trick is to infect
pigtailed macaques that naturally lack the HIV-restricting protein TRIM5 with an
HIV strain encoding the simian immunodeficiency virus Vif to antagonize several
macaque proteins that would otherwise restrict HIV-1 infection. These measures,
accompanied by transient CD8 T cell depletion to alleviate the immune pressure
and increase initial viral population size, allow for the replication and successful
infection of the new host. The resulting adapted virus is capable of causing an
immunodeficiency syndrome that reproduces the key features of the disease inhumans, providing a new animal model to dissect the pathogenesis of HIV infection. Importantly, only CD8+ T-cell-depleted
monkeys progress with immunodeficiency, whereas animals with intact CD8+ T cell populations seroconvert and control
the infection. Immune insult during the primary phase of the infection may thus be a major contributor to the clinical
outcome of the disease.
Hatziioannou, T., et al. (2014). Science 344, 1401–1405.Baby Antibodies Broadly Neutralize
Only a subset of adults infectedwith HIV-1 develop broadly neutralizing antibodies (bNAbs), which are thought to take years to
develop because of the need to accumulate an unusually high number of somatic hypermutations. To require the needed
breadth entails repeated cycles of maturation in the germinal centers. A recent report from Julie Overbaugh and colleagues
challenges this notion by showing that bNAbs quickly develop in infants exposed to HIV infection in utero. These antibodies
are not due to passive transfer of maternal antibodies through the placenta and represent de novo generation of antibodies by
the infants B cells. In many cases, a peak in breadth is observed as short as 1 year after infection. A high set point viral load
seems to be the strongest predictive factor of the quick development of bNAbs. Although it is still unclear how antibodies
develop breadth so quickly, these findings provide a proof of concept that, under the right conditions, it is possible to elicit
a fast and efficient HIV-neutralizing response.
Goo, L., et al. (2014). Nat. Med. 20, 655–660.The Right Spot to Integrate and Persist
HIV patients undergoing long-term treatment with combined antiretroviral therapy (cART) frequently show the emergence
of identical viruses, suggesting the possibility that the clonal expansion of some HIV-infected cells may play a role in viral
persistence. Because HIV has the ability to integrate its DNA into a very large number of sites in the human genome, integra-
tion sites can be used as markers of clonally expanded cells. Hughes and colleagues followed five patients chronically
infected with HIV to determine the sites of integration of the virus in peripheral blood CD4+ T cells. Before the beginning
of cART, all patients present diverse viral populations that converge to identical populations after prolonged cART. The
surprises come from the longitudinal analysis of the HIV-infected cells that persist despite the treatment. Though HIV
integrates preferentially into actively transcribed genes, persistence is often associated with integration in genes known
to be associated with cellular growth and mitosis. These cells clonally expand, and their progeny can be detected for
longer than a decade after the initial infection. Similar results are also reported by an independent study by Frenkel and
colleagues. They show that the sites of integration do vary between patients and that there is, to some extent, heterogeneity
in the insertion sites in different cells from the same patients. Nonetheless, insertions into specific regions such as theCell 158, July 31, 2014 ª2014 Elsevier Inc. 469
oncogene BACH2 are clearly more frequently observed. Many questions remain. It is unclear whether the selected clonally
expanded cells produce infective virions, and therefore it is difficult to estimate their precise contribution for the perpetuation
of the chronic infection. Still, these findings strongly suggest that curative HIV therapies will need to block the expansion of
the infected cells and unveil the possibility that integration of HIV at specific sites may affect the biology of the cells.
Maldarelli, F., et al. (2014). Science 345, 179–183.
Wagner, T.A., et al. (2014). Science. Published online July 10, 2014. http://dx.doi.org/10.1126/science.1256304.Stochastic fluctuations in HIV-encoded
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Weinberger.Make a Little Noise to Wake Up Dormant Virus
Upon HIV infection, the virus can enter a long-lived proviral latent state during which
it is not susceptible to antiretroviral therapy. This latent viral reservoir represents
the major obstacle to cure HIV infection. Although small molecules that reactivate
the virus by promoting increases in the mean level of HIV gene expression have
been identified, thus far they have been unable to efficiently reactivate latency.
Leor Weinberger and colleagues hypothesize whether it is possible to improve
the efficacy of these drugs using agents that affect ‘‘noise’’ or fluctuations around
the mean gene-expression level. Indeed, they find that modulating noise in gene
expression increases the chances that latent HIV will cross the threshold for latent
reactivation. A small-molecule library screen for drugs that modulates noise in gene
expression revealed 80 candidates that promote noise but do not change HIV
mean expression and therefore would be neglected in conventional screenings.Importantly, these noise-inducing drugs synergize with traditional transcriptional activators, promoting increased HIV reac-
tivation in vitro, with minimal off-target effects in the host cells. Further work will be required to assess the efficacy of this
synergy in vivo, but the concept of ‘‘noise screening’’ may represent a new general approach to define synergistic drug com-
binations and manipulate diverse cell-fate decisions.
Dar, R.D., et al. (2014). Science 344, 1392–1396.There Is a Place and Time for Interferon in HIV Infection
Despite its potent effect in triggering antiviral responses, the role of interferon in HIV infection remains enigmatic. Early reports
could not detect beneficial effects of interferon administration to patients chronically infectedwith HIV, many of whompresent
high interferon levels even before the beginning of the treatment. Now, Douek and colleagues report that blocking IFN-I
receptors in rhesus macaques infected with the simian immunodeficiency virus (SIV) results in faster progression to AIDS.
In line with these results, pretreatment of macaqueswith IFN-a2a limits systemic spread of the virus. Paradoxically, continued
treatment with IFN-a2a leads to an ‘‘IFN-desensitized’’ state, decreased antiviral gene expression, and increased suscepti-
bility to infection manifested by increased cell-associated virus load and greater depletion of helper T cells. Inflammation and
type I interferon production thus might be key in containing the early local infection. However, as the disease progresses and
the host becomes desensitized, this balance changes and interferon turns to contribute to immunopathology. The complex
temporal dynamic of the innate immune response to retroviruses in primates shows that pro- and anti-inflammatory therapies
for HIV need to be approached with caution and must take into account the dual effects of interferon signaling during the
course of the infection.
Sandler, N.G., et al (2014). Nature. Published online July 9, 2014. http://dx.doi.org/10.1038/nature13554.
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